logo
  Join        Login             Stock Quote

Alnylam (ALNY) Presents Pre-Clinical Data To Treat Hemophilia, Other Bleeding Disorders

 December 10, 2012 12:33 PM
 


(By Balaseshan) Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) said it has presented new pre-clinical data on RNAi therapeutics for the treatment of hemophilia and other bleeding disorders at the 54th American Society of Hematology Annual Meeting.

Alnylam scientists presented data showing that ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), yields potent, dose-dependent, and durable knockdown of AT in non-human primates (NHPs) with an up to four-fold increase in thrombin generation.

Alnylam's program in hemophilia comprises part of its "Alnylam 5x15" product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015.

[Related -Bernanke's Comments Sends Futures Higher; Microsoft Corporation (MSFT) In Focus]

Alnylam scientists showed that subcutaneous administration of ALN-AT3 in NHPs results in potent, dose-dependent, and durable knockdown in serum AT, resulting in significant increases in thrombin generation. Alnylam expects to file an investigational new drug (IND) application for ALN-AT3 in mid-2013.

In addition, results from Alnylam's ALN-AT3 program will be discussed at an upcoming RNAi Roundtable on conjugate delivery that the company will host on December 14 at 11:00 am. The discussion will focus on progress with the company's proprietary GalNAc-conjugate platform to deliver RNAi therapeutics with subcutaneous dose administration.

[Related -Alnylam Pharma (ALNY) Begins New Transthyretin-Mediated Amyloidosis Study]

The roundtable will also include a review of the company's two leading conjugate programs: ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis (ATTR) and ALN-AT3 for the treatment of hemophilia and other bleeding disorders.

Hemophilias are hereditary disorders caused by genetic deficiencies of various blood clotting factors, resulting in recurrent bleeds into joints, muscles, and other major internal organs.

ALNY is trading up 4.68% at $17.43 on Monday. The stock has been trading between $6.88 and $21.38 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChipotle Mexican Grill, Inc. (CMG) Q2 Earnings Preview: Will Higher Traffic Offset Higher Costs the Key

Chipotle Mexican Grill, Inc. (NYSE:CMG) will host a conference call to discuss second quarter 2014 read on...

article imageNetflix, Inc. (NFLX) Q2 Earnings Preview: The Ruby Month for a Reason

Netflix, Inc. (NASDAQ:NFLX) will post its second-quarter 2014 financial results and business outlook on its read on...

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Good Way To End The Week
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.